Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
Journal of Clinical Pharmacology|March 24, 2007
Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical developmentMary Ann Mascelli, Honghui Zhou, Raymond Sweet, et al.Journal of Clinical Pharmacology|April 11, 2008
Population pharmacokinetics of infliximab in patients with ankylosing spondylitisZhenhua Xu, Kathleen Seitz, Adedigbo Fasanmade, et al.Journal of Immunological Methods|September 4, 2004
Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatantsUma Prabhakar, Edward Eirikis, Manjula Reddy, et al.European Journal of Clinical Pharmacology|September 17, 2009
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisAdedigbo A Fasanmade, Omoniyi J Adedokun, Joyce Ford, et al.Mabs|November 28, 2012
A novel approach for the simultaneous quantification of a therapeutic monoclonal antibody in serum produced from two distinct host cell linesBrian J Geist, Darryl Davis, Thomas McIntosh, et al.Mabs|July 10, 2018
Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agentsXiling Jiang, Xi Chen, Thomas J Carpenter, et al.British Journal of Clinical Pharmacology|March 12, 2011
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human studyZhenhua Xu, Esther Bouman-Thio, Craig Comisar, et al.British Journal of Clinical Pharmacology|October 10, 2012
Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human studyBart van Hartingsveldt, Ivo P Nnane, Esther Bouman-Thio, et al.Journal of Clinical Pharmacology|June 9, 2015
Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approachYanli Zhuang, Dick E de Vries, Zhenhua Xu, et al.Journal of Clinical Pharmacology|January 31, 2009
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasisYaowei Zhu, Chuanpu Hu, Ming Lu, et al.Pageof 6